Factors influencing 5-year persistence to adjuvant endocrine therapy in young women with breast cancer

Autor: Eleonora Pagan, Monica Ruggeri, Nadia Bianco, Eraldo Oreste Bucci, Rossella Graffeo, Markus Borner, Monica Giordano, Lorenzo Gianni, Manuela Rabaglio, Andrea Freschi, Elisabetta Cretella, Elena Seles, Alberto Farolfi, Edda Simoncini, Mariangela Ciccarese, Daniel Rauch, Adolfo Favaretto, Friedemann Honecker, Rossana Berardi, Alessandra Franzetti-Pellanda, Shari Gelber, Ann H. Partridge, Aron Goldhirsch, Vincenzo Bagnardi, Olivia Pagani, Karin Ribi

Publikováno v: Breast, Vol 77, Iss , Pp 103765- (2024)

Purpose: Although younger age has been negatively associated with persistence to adjuvant endocrine therapy (ET), factors contributing to non-persistence remain poorly understood. We assessed factors associated with non-persistence to ET and describe

Externí odkaz: https://doaj.org/article/570c5e4f78064981bd0ebc4df466fd94

Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10)

Autor: Bernhard C. Pestalozzi, Christoph Tausch, Konstantin J. Dedes, Christoph Rochlitz, Stefan Zimmermann, Roger von Moos, Ralph Winterhalder, Thomas Ruhstaller, Andreas Mueller, Katharina Buser, Markus Borner, Urban Novak, Catrina Uhlmann Nussbaum, Bettina Seifert, Martin Bigler, Vincent Bize, Simona Berardi Vilei, Christoph Rageth, Stefan Aebi, The Swiss Group for Clinical Cancer Research (SAKK)

Publikováno v: BMC Cancer, Vol 17, Iss 1, Pp 1-10 (2017)

Abstract Background To evaluate the effect of Recurrence Score® results (RS; Oncotype DX® multigene assay ODX) on treatment recommendations by Swiss multidisciplinary tumor boards (TB). Methods SAKK 26/10 is a multicenter, prospective cohort study

Externí odkaz: https://doaj.org/article/c9a8ea8a27db4f48921538bf341f9e66

Balancing Conservation with National Development: A Socio-Economic Case Study of the Alternatives to the Serengeti Road.

Autor: J Grant C Hopcraft, Gerald Bigurube, James Daudi Lembeli, Markus Borner

Publikováno v: PLoS ONE, Vol 10, Iss 7, p e0130577 (2015)

Developing countries often have rich natural resources but poor infrastructure to capitalize on them, which leads to significant challenges in terms of balancing poverty alleviation with conservation. The underlying premise in development strategies

Externí odkaz: https://doaj.org/article/ff0f5ac016e94f3d823e3fc4419d0f51

Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol

Autor: Gerhardt Attard, Laura Murphy, Noel W Clarke, Ashwin Sachdeva, Craig Jones, Alex Hoyle, William Cross, Robert J Jones, Christopher C Parker, Silke Gillessen, Adrian Cook, Chris Brawley, Clare Gilson, Hannah Rush, Hoda Abdel-Aty, Claire L Amos, Claire Murphy, Simon Chowdhury, Zafar Malik, J Martin Russell, Nazia Parkar, Cheryl Pugh, Carlos Diaz-Montana, Carmel Pezaro, Warren Grant, Helen Saxby, Ian Pedley, Joe M O'Sullivan, Alison Birtle, Joanna Gale, Narayanan Srihari, Carys Thomas, Jacob Tanguay, John Wagstaff, Prantik Das, Emma Gray, Mymoona Alzouebi, Omi Parikh, Angus Robinson, Amir H Montazeri, James Wylie, Anjali Zarkar, Richard Cathomas, Michael D Brown, Yatin Jain, David P Dearnaley, Malcolm D Mason, Duncan Gilbert, Ruth E Langley, Robin Millman, David Matheson, Matthew R Sydes, Louise C Brown, Mahesh K B Parmar, Nicholas D James, Elin Jones, Katherine Hyde, Hilary Glen, Sarah Needleman, Ursula McGovern, Denise Sheehan, Sangeeta Paisey, Richard Shaffer, Mark Beresford, Emilio Porfiri, David Fackrell, Ling Lee, Thiagarajan Sreenivasan, Sue Brock, Simon Brown, Amit Bahl, Mike Smith-Howell, Cathryn Woodward, Mau-Don Phan, Danish Mazhar, Krishna Narahari, Fiona Douglas, Anil Kumar, Abdel Hamid, Azman Ibrahim, Dakshinamoorthy Muthukumar, Matthew Simms, Jane Worlding, Anna Tran, Mohammed Kagzi, Virgil Sivoglo, Benjamin Masters, Pek Keng-Koh, Caroline Manetta, Duncan McLaren, Nishi Gupta, Stergios Boussios, Henry Taylor, John Graham, Carla Perna, Lucinda Melcher, Ami Sabharwal, Uschi Hofmann, Robert Dealey, Neil McPhail, Robert Brierly, Lisa Capaldi, Norma Sidek, Peter Whelan, Peter Robson, Alison Falconer, Sarah Rudman, Sindu Vivekanandan, Vinod Mullessey, Maria Vilarino-Varela, Vincent Khoo, Karen Tipples, Mehran Afshar, Patryk Brulinski, Vijay Sangar, Clive Peedell, Ashraf Azzabi, Peter Hoskin, Viwod Mullassery, Santhanam Sundar, Yakhub Khan, Ruth Conroy, Andrew Protheroe, Judith Carser, Paul Rogers, Kathryn Tarver, Stephanie Gibbs, Mohammad Muneeb Khan, Mohan Hingorani, Simon Crabb, Manal Alameddine, Neeraj Bhalla, Robert Hughes, John Logue, Darren Leaning, Salil Vengalil, Daniel Ford, Georgina Walker, Ahmed Shaheen, Omar Khan, Andrew Chan, Imtiaz Ahmed, Serena Hilman, Ian Sayers, Ashok Nikapota, David Bloomfield, Tim Porter, Joji Joseph, Cyrill Rentsch, Ricardo Pereira Mestre, Enrico Roggero, Jörg Beyer, Markus Borner, Raeto Strebel, Dominik Berthold, Daniel Engeler, Hubert John, Razvan Popescu, Donat Durr

Publikováno v: STAMPEDE investigators, Attard, G, Murphy, L, Clarke, N W, Sachdeva, A, Jones, C, Hoyle, A, Cross, W, Jones, R J, Parker, C C, Gillessen, S, Cook, A, Brawley, C, Gilson, C, Rush, H, Abdel-Aty, H, Amos, C L, Murphy, C, Chowdhury, S, Malik, Z, Russell, J M, Parkar, N, Pugh, C, Diaz-Montana, C, Pezaro, C, Grant, W, Saxby, H, Pedley, I, O'Sullivan, J M, Birtle, A, Gale, J, Srihari, N, Thomas, C, Tanguay, J, Wagstaff, J, Das, P, Gray, E, Alzouebi, M, Parikh, O, Robinson, A, Montazeri, A H, Wylie, J, Zarkar, A, Cathomas, R, Brown, M D, Jain, Y, Dearnaley, D P, Mason, M D, Gilbert, D, Langley, R E & Millman, R 2023, ' Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol ', Lancet Oncology, vol. 24, no. 5, pp. 443-456 . https://doi.org/10.1016/S1470-2045(23)00148-1
Attard, G, Murphy, L, Clarke, N W, Sachdeva, A, Jones, C, Hoyle, A, Cross, W, Jones, R J, Parker, C C, Gillessen, S, Cook, A, Brawley, C, Gilson, C, Rush, H, Abdel-Aty, H, Amos, C L, Murphy, C, Chowdhury, S, Malik, Z, Russell, J M, Parkar, N, Pugh, C, Diaz-Montana, C, Pezaro, C, Grant, W, Saxby, H, Pedley, I, O'Sullivan, J M, Birtle, A, Gale, J, Srihari, N, Thomas, C, Tanguay, J, Wagstaff, J, Das, P, Gray, E, Alzouebi, M, Parikh, O, Robinson, A, Montazeri, A H, Wylie, J, Zarkar, A, Cathomas, R, Brown, M D, Jain, Y, Dearnaley, D P, Mason, M D, Gilbert, D, Langley, R E & Millman, R 2023, ' Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy : final results from two randomised phase 3 trials of the STAMPEDE platform protocol ', The Lancet. Oncology, vol. 24, no. 5, pp. 443-456 . https://doi.org/10.1016/S1470-2045(23)00148-1

Background: Abiraterone acetate plus prednisolone (herein referred to as abiraterone) or enzalutamide added at the start of androgen deprivation therapy improves outcomes for patients with metastatic prostate cancer. Here, we aimed to evaluate long-t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47ca84b5aff90123f3e4082a739e1def
https://doi.org/10.1016/s1470-2045(23)00148-1

Employment trajectories of young women with breast cancer: an ongoing prospective cohort study in Italy and Switzerland

Autor: Karin Ribi, Eleonora Pagan, Isabella Sala, Monica Ruggeri, Nadia Bianco, Eraldo Oreste Bucci, Rossella Graffeo, Markus Borner, Monica Giordano, Lorenzo Gianni, Manuela Rabaglio, Andrea Freschi, Elisabetta Cretella, Elena Seles, Alberto Farolfi, Edda Simoncini, Mariangela Ciccarese, Daniel Rauch, Adolfo Favaretto, Agnes Glaus, Rossana Berardi, Alessandra Franzetti-Pellanda, Vincenzo Bagnardi, Shari Gelber, Ann H. Partridge, Aron Goldhirsch, Olivia Pagani

Publikováno v: Journal of Cancer Survivorship.

PURPOSE Despite extensive research on cancer and work-related outcomes, evidence from longitudinal cohort studies is limited, especially in young women with breast cancer (BC). We aimed to investigate employment trajectories in young BC survivors and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb885129493a63e4c182d297532ba0f4
https://doi.org/10.1007/s11764-022-01222-y